Procainamide

Procainamide
Clinical data
Pronunciation/prˈknəmd/
Trade namesPronestyl, Procan, Procanbid, others
AHFS/Drugs.comMonograph
Routes of
administration
IV, IM, by mouth
ATC code
Legal status
Legal status
  • UK: POM (Prescription only)
Pharmacokinetic data
Bioavailability85% (by mouth)
Protein binding15 to 20%
MetabolismLiver (CYP2D6-mediated)
Elimination half-life~2.5 to 4.5 hours
ExcretionKidney
Identifiers
  • 4-amino-N-(2-diethylaminoethyl) benzamide
CAS Number
PubChem CID
IUPHAR/BPS
DrugBank
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard100.000.072 Edit this at Wikidata
Chemical and physical data
FormulaC13H21N3O
Molar mass235.331 g·mol−1
3D model (JSmol)
  • O=C(c1ccc(N)cc1)NCCN(CC)CC
  • InChI=1S/C13H21N3O/c1-3-16(4-2)10-9-15-13(17)11-5-7-12(14)8-6-11/h5-8H,3-4,9-10,14H2,1-2H3,(H,15,17) checkY
  • Key:REQCZEXYDRLIBE-UHFFFAOYSA-N checkY
  (verify)

Procainamide (PCA) is a medication of the antiarrhythmic class used for the treatment of cardiac arrhythmias. It is a sodium channel blocker of cardiomyocytes; thus it is classified by the Vaughan Williams classification system as class Ia. In addition to blocking the INa current, it inhibits the IKr rectifier K+ current.[1] Procainamide is also known to induce a voltage-dependent open channel block on the batrachotoxin (BTX)-activated sodium channels in cardiomyocytes.[2]

  1. ^ Osadchii OE (August 2014). "Procainamide and lidocaine produce dissimilar changes in ventricular repolarization and arrhythmogenicity in guinea-pig". Fundamental & Clinical Pharmacology. 28 (4): 382–393. doi:10.1111/fcp.12046. PMID 23952942. S2CID 5086017.
  2. ^ Zamponi GW, Sui X, Codding PW, French RJ (December 1993). "Dual actions of procainamide on batrachotoxin-activated sodium channels: open channel block and prevention of inactivation". Biophysical Journal. 65 (6): 2324–2334. Bibcode:1993BpJ....65.2324Z. doi:10.1016/S0006-3495(93)81291-8. PMC 1225974. PMID 8312472.